Form 8-K ImmunoGen, Inc. For: May 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Wall St set for best week since April as payrolls surprise eases rate-hike jitters
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Oil gains on US jobs report, worries over peace talks
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Stocks close lower as investors eye Mideast talks, earnings
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Immunogen Inc. (IMGN) Elahere Data 'Simply Mirvelous!' - BMO
May 3, 2023 7:39 AM EDTBMO Capital analyst Etzer Darout reiterated an Outperform rating and $19.00 price target on Immunogen Inc. (NASDAQ: IMGN) following positive phase 3 data on ELAHERE. The analyst called the results "simply mirvelous!'
The analyst commented, "This morning IMGN announced that the Phase 3 MIRASOL trial studying... More
Immunogen Inc. (IMGN) PT Raised to $15 at Truist Securities on 'Home Run' Data
May 3, 2023 7:35 AM EDTTruist Securities analyst Asthika Goonewarden raised the price target on Immunogen Inc. (NASDAQ: IMGN) to $15.00 (from $11.00) while maintaining a Buy rating, calling today's data a "home run."
The analyst commented, "We view the topline data reported this morning as a home run. MIRASOL not... More
